Abstract
Butyrylcholinesterase (BChE) is not only an important protein for development of anti-cocaine medication but also an established drug target to develop new treatment for Alzheimer’s disease (AD). The molecular basis of interaction of a new series of quinazolinimine derivatives as BChE inhibitors has been studied by molecular docking and molecular dynamics (MD) simulations. The molecular docking and MD simulations revealed that all of these inhibitors bind with BChE in similar binding mode. Based on the similar binding mode, we have carried out three-dimensional quantitative structure–activity relationship (3D-QSAR) studies on these inhibitors using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), to understand the structure–activity correlation of this series of inhibitors and to develop predictive models that could be used in the design of new inhibitors of BChE. The study has resulted in satisfactory 3D-QSAR models. We have also developed ligand-based 3D-QSAR models. The contour maps obtained from the 3D-QSAR models in combination with the simulated binding structures help to better interpret the structure–activity relationship and is consistent with available experimental activity data. The satisfactory 3D-QSAR models strongly suggest that the determined BChE-inhibitor binding modes are reasonable. The identified binding modes and developed 3D-QSAR models for these BChE inhibitors are expected to be valuable for rational design of new BChE inhibitors that may be valuable in the treatment of Alzheimer’s disease.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig2_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig3_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig4_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig5_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig6_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig7_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig8_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig9_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00214-011-0965-1/MediaObjects/214_2011_965_Fig10_HTML.gif)
Similar content being viewed by others
References
Carreiras MC, Marco JL (2004) Curr Pharm Des 10:3167–3175
Campiani G, Fattorusso C, Butini S, Gaeta A, Agnusdei M, Gemma S, Persico M, Catalanotti B, Savini L, Nacci V, Novellino E, Holloway HW, Greig NH, Belinskaya T, Fedorko JM, Saxena A (2005) J Med Chem 48:1919–1929
Salloway S, Mintzer J, Weiner MF, Cummings JL (2008) Alzheimers Dement 4:65–79
Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C (2005) J Med Chem 48:360–363
Schliebs R, Arendt T (2006) J Neural Transm 113:1625–1644
Decker M (2005) Eur J Med Chem 40:305–313
Zaheer-ul H, Uddin R, Yuan H, Petukhov PA, Choudhary MI, Madura JD (2008) J Chem Inf Model 48:1092–1103
Pan L, Tan J-H, Hou J-Q, Huang S-L, Gu L-Q, Huang Z-S (2008) Bioorg Med Chem Lett 18:3790–3793
Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M (2008) Bioorg Med Chem Lett 18:2905–2909
Zheng F, Zhan C-G (2008) J Comput Aided Mol Des 22:661–671
Zhan C-G, Zheng F, Landry DW (2003) J Am Chem Soc 125:2462–2474
Gorelick DA (1997) Drug Alcohol Depend 48:159–165
Yu Q-S, Holloway HW, Utsuki T, Brossi A, Greig NH (1999) J Med Chem 42:1855–1861
Mesulam M-M, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002) Neuroscience 110:627–639
Greig NH, Utsuki DK, Ingram DK, Wang Y, Pepeu G, Scali C, Yu Q-S, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K, Sambamurti K, Brossi A, Lahiri DK (2005) Proc Natl Acad Sci USA 102:17213–17218
Duysen EG, Li B, Darvesh S, Lockridge O (2007) Toxicology 233:60–69
Li B, Stribley JA, Ticu A, **e W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, Lockridge O (2000) J Neurochem 75:1320–1331
Decker M, Krauth F, Lehmann J (2006) Bioorg Med Chem 14:1966–1977
Decker M (2006) J Med Chem 49:5411–5413
Decker M, Kraus B, Heilmann J (2008) Bioorg Med Chem 16:4252–4261
Jorgensen WL (2009) Acc Chem Res 42:724–733
Joseph-McCarthy D (1999) Pharmacol Therap 84:179–191
Davis AM, Teague SJ, Kleywegt GJ (2003) Angew Chem Int Ed 42:2718–2736
Martin YC (1998) Perspec Drug Discov Design 12:3–23
Cramer RD, Patterson DE, Bunce JDJ (1988) Am Chem Soc 110:5959–5967
Kubinyi H (ed) (1993) 3D-QSAR in drug design. Theory, methods and applications. ESCOM, Leiden (NL)
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130–4146
Bohm M, Sturzebecher J, Klebe G (1999) J Med Chem 42:458–477
AbdulHameed MDM, Hamza A, Liu J, Huang X, Zhan C-GJ (2008) Chem Inf Mod 48:179–185
Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N (2004) J Med Chem 47:385–399
Yang G-F, Lu H-T, **ong Y, Zhan C-G (2006) Bioorg Med Chem 14:1462–1473
Debnath AK (2001) Mini Rev Med Chem 1:187–195
Abdulhameed MDM, Hamza A, Liu J, Zhan C-GJ (2008) Chem Inf Model 48:1760–1772
Besler BH, Merz KM Jr, Kollman PA (1990) J Comp Chem 11:431–439
Singh UC, Kollman PA (1984) J Comp Chem 5:129–145
Rarey M, Kramer B, Lengauer T, Kleb G (1996) J Mol Biol 261:470–489
Rarey M, Wefing S, Lengauer T (1996) J Comput Aided Mol Design 10:41–54
AbdulHameed MDM, Hamza A, Zhan C-G (2006) J Phys Chem B 110:26365–26374
Case DA, Darden TA, III Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Wang B, Pearlman DA, Crowley M, Brozell S, Tsui V, Gohlke H, Mongan J, Hornak V, Cui G, Beroza P, Schafmeister C, Caldwell JW, Ross WS, Kollman PA (2004) AMBER 8. University of California, San Francisco
Jorgensen WL, Chandrasekhar J, Madura JD, Klein MLJ (1983) J Chem Phys 79:926–935
Berendsen HC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR (1984) J Chem Phys 81:3684–3690
Ryckaert JP, Ciccotti G, Berendsen HC (1977) J Comput Phys 23:327–341
Essmann U, Perera L, Berkowitz ML, Darden TA, Lee H, Pedersen LG (1995) J Chem Phys 103:8577–8593
Datar P, Desai P, Coutinho E, Iyer K (2002) J Mol Model 8:290–301
Bush BL, Nachbar RB (1993) J Comp Aided Mol Design 7:587–619
Tripos Associates, Inc., 1699 S. Hanley, St.Louis MI 63144, USA
Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F (2003) J Biol Chem 278:41141–41147
Sperandiodasilva GM, Sant’Anna CMR, Barreiro EJ (2004) Bioorg Med Chem 12:3159–3166
Acknowledgments
The research was supported by NIH (grant R01 DA013930 to CGZ). CSR worked in CGZ’s laboratory as a NIDA Summer Research Fellow (from School of Informatics, Indiana University) through a supplemental award (R01 DA013930-06S2 to CGZ). The authors also acknowledge the Center for Computational Sciences (CCS) at University of Kentucky for supercomputing time on IBM X-series Cluster with 340 nodes or 1,360 processors.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
AbdulHameed, M.D.M., Liu, J., Pan, Y. et al. Microscopic binding of butyrylcholinesterase with quinazolinimine derivatives and the structure–activity correlation. Theor Chem Acc 130, 69–82 (2011). https://doi.org/10.1007/s00214-011-0965-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00214-011-0965-1